MGMT status is a well-known predictor of chemosensitivity in glioblastoma [47]; thus, in order to understand its role in astrocytoma, we investigated the MSKCC chemotherapy-treated cohort and the CGGA recurrent chemotherapy-treated cohort where the MGMT statuses were known and performed survival analysis based on TP53 mutation and YAP1 mRNA expression levels, respectively. This evidence concerns the gene TP53 and astrocytoma (excluding glioblastoma).